Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience

BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic...

Full description

Saved in:
Bibliographic Details
Published inTranslational oncology Vol. 13; no. 2; pp. 295 - 299
Main Authors Aggerholm-Pedersen, Ninna, Rossen, Phillip, Rose, Hanne, Safwat, Akmal
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.02.2020
Neoplasia Press
Elsevier
Subjects
Original article
Online AccessGet full text

Cover

Abstract BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy. METHODS: All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed. RESULTS: Nineteen patients were identified. The median age was 38 years (range 18–62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity. CONCLUSION: Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed.
AbstractList The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy. All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed. Nineteen patients were identified. The median age was 38 years (range 18-62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity. Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed.
BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy. METHODS: All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed. RESULTS: Nineteen patients were identified. The median age was 38 years (range 18–62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity. CONCLUSION: Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed.
BACKGROUNDThe effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy. METHODSAll patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed. RESULTSNineteen patients were identified. The median age was 38 years (range 18-62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity. CONCLUSIONOff-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed.
BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy. METHODS: All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed. RESULTS: Nineteen patients were identified. The median age was 38 years (range 18–62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity. CONCLUSION: Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed.
Author Aggerholm-Pedersen, Ninna
Rossen, Phillip
Rose, Hanne
Safwat, Akmal
AuthorAffiliation Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
AuthorAffiliation_xml – name: Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
Author_xml – sequence: 1
  givenname: Ninna
  surname: Aggerholm-Pedersen
  fullname: Aggerholm-Pedersen, Ninna
  email: ninnpe@rm.dk
– sequence: 2
  givenname: Phillip
  surname: Rossen
  fullname: Rossen, Phillip
– sequence: 3
  givenname: Hanne
  surname: Rose
  fullname: Rose, Hanne
– sequence: 4
  givenname: Akmal
  surname: Safwat
  fullname: Safwat, Akmal
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31875575$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1v1DAQhi3Uin7AP0AoRy4b_BE7MQcErApUqtRK7N2aOOPWq8Re7GwF_fV1u6W0l55szcfzzsx7RPZCDEjIO0ZrRpn6uK7nBCVWc8p0zXhNKXtFDpkWaiG5EHtP_gfkKOc1pYppzl-TA8G6VspWHpIvF3ATNxB8X_lQzVdYrRLCPGGYq-iqb0Wz-gXJxgnyp2o5-uAtjNXJnw0mj8HiG7LvYMz49uE9JqvvJ6vlz8XZ-Y_T5dezhZVcz4vBciiDIsWmo9pZ6VSjqaSd05Ir3jSKchBMOkF73rUgre37oRGUUQu9EsfkdIcdIqzNJvkJ0l8TwZv7QEyXBtLs7YjGDdhw0Mh51zdy0LrwO9E6a1UPopeF9XnH2mz7CQdbdk0wPoM-zwR_ZS7jtVFaMM5YAXx4AKT4e4t5NpPPFscRAsZtNuXitNW80bqUNrtSm2LOCd2jDKPmzkezNjsfzZ2PhnFTfCxt75-O-Nj0z7j_O2C5-bXHZLK992PwCe1cruJfVrgFOI6x6Q
CitedBy_id crossref_primary_10_1002_cam4_4849
crossref_primary_10_3390_cancers12082130
crossref_primary_10_3390_medicina57020141
crossref_primary_10_3390_jpm13050730
crossref_primary_10_1016_j_jbo_2023_100511
crossref_primary_10_1007_s10456_020_09716_y
crossref_primary_10_3390_ijms25073834
crossref_primary_10_17816_vto624147
crossref_primary_10_3390_ijms231810721
crossref_primary_10_1002_pbc_29084
crossref_primary_10_1038_s41598_021_87553_9
crossref_primary_10_1080_08880018_2023_2182854
crossref_primary_10_3389_fonc_2023_1013359
crossref_primary_10_1021_acsomega_2c00518
crossref_primary_10_1038_s41571_021_00519_8
crossref_primary_10_1111_1759_7714_15208
crossref_primary_10_3390_ijms21207595
crossref_primary_10_1007_s12254_021_00728_y
crossref_primary_10_1089_ten_teb_2023_0106
crossref_primary_10_18632_oncoscience_587
crossref_primary_10_3390_pharmaceutics15020664
crossref_primary_10_1002_ctd2_202
crossref_primary_10_21682_2311_1267_2021_8_1_57_63
Cites_doi 10.1093/annonc/mdy500
10.1158/1078-0432.CCR-09-0816
10.1016/S1470-2045(14)71136-2
10.1080/0284186X.2018.1503714
10.1002/cncr.23437
10.1093/jnci/dju329
10.1002/cncr.24562
10.1016/j.critrevonc.2010.02.012
10.1016/S0140-6736(12)60651-5
10.1200/JCO.2010.30.9674
10.3109/0284186X.2014.948062
10.1007/s12032-018-1180-x
10.1016/S1470-2045(18)30742-3
10.1200/JCO.2003.08.132
10.3109/0284186X.2014.971938
10.1002/cncr.29426
10.2147/CLEP.S41835
ContentType Journal Article
Copyright 2019 The Authors
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
2019 The Authors 2019
Copyright_xml – notice: 2019 The Authors
– notice: Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
– notice: 2019 The Authors 2019
DBID 6I.
AAFTH
NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1016/j.tranon.2019.12.001
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1936-5233
EndPage 299
ExternalDocumentID oai_doaj_org_article_fde42a9e228b45d99262837fcc6ba3b5
10_1016_j_tranon_2019_12_001
31875575
S1936523319304073
Genre Journal Article
GroupedDBID ---
.1-
.FO
0SF
1P~
29Q
2WC
4.4
457
53G
5VS
6I.
AACTN
AAEDT
AAEDW
AAFTH
AAIKJ
AAKDD
AALRI
AAXUO
ABMAC
ACGFS
ADBBV
ADEZE
AENEX
AEVXI
AEXQZ
AFCTW
AFRHN
AFTJW
AGHFR
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOIJS
BAWUL
BCNDV
DIK
E3Z
EBS
EJD
F5P
FDB
GROUPED_DOAJ
GX1
HYE
IPNFZ
IXB
KQ8
M~E
NCXOZ
OC~
OK1
OO-
RIG
ROL
RPM
SSZ
TR2
Z5R
0R~
ADVLN
AFJKZ
AKRWK
NPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c529t-dc2a201e0e4809fc5f6490508f9526244602a315f30b287a5ccbbd43010cab63
IEDL.DBID RPM
ISSN 1936-5233
IngestDate Tue Oct 22 15:11:03 EDT 2024
Tue Sep 17 21:28:02 EDT 2024
Fri Oct 25 22:17:36 EDT 2024
Thu Sep 26 19:22:23 EDT 2024
Sat Sep 28 08:29:57 EDT 2024
Wed May 17 02:16:52 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c529t-dc2a201e0e4809fc5f6490508f9526244602a315f30b287a5ccbbd43010cab63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931211/
PMID 31875575
PQID 2330792499
PQPubID 23479
PageCount 5
ParticipantIDs doaj_primary_oai_doaj_org_article_fde42a9e228b45d99262837fcc6ba3b5
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6931211
proquest_miscellaneous_2330792499
crossref_primary_10_1016_j_tranon_2019_12_001
pubmed_primary_31875575
elsevier_sciencedirect_doi_10_1016_j_tranon_2019_12_001
PublicationCentury 2000
PublicationDate 2020-02-01
PublicationDateYYYYMMDD 2020-02-01
PublicationDate_xml – month: 02
  year: 2020
  text: 2020-02-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Translational oncology
PublicationTitleAlternate Transl Oncol
PublicationYear 2020
Publisher Elsevier Inc
Neoplasia Press
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Neoplasia Press
– name: Elsevier
References Coens, van der Graaf, Blay, Chawla, Judson, Sanfilippo, Manson, Hodge, Marreaud, Prins (bib5) 2015; 121
Grignani, Palmerini, Ferraresi, D'Ambrosio, Bertulli, Asaftei, Tamburini, Pignochino, Sangiolo, Marchesi (bib13) 2015; 16
Seto, Song, Trieu, Yu, Sidhu, Liu, Sam, Pan (bib19) 2019; 7
Urbonas, Schadendorf, Zimmer, Danson, Marshall, Corrie, Wheater, Plummer, Mauch, Scudder (bib21) 2019; 30
Schutz, Choueiri, Sternberg (bib3) 2011; 77
Abdeen, Chou, Healey, Khanna, Osborne, Hewitt, Kim, Wang, Moody, Gorlick (bib6) 2009; 115
Goyal, Shah, Khan, Danish, Haffty (bib22) 2012; 2012
Fox, Aplenc, Bagatell, Chuk, Dombi, Goodspeed, Goodwin, Kromplewski, Jayaprakash, Marotti (bib18) 2010; 28
Raciborska, Bilska (bib12) 2018; 35
Yukata, Matsui, Goto, Kubo, Yasui (bib10) 2005; 25
Safwat, Boysen, Lucke, Rossen (bib15) 2014; 53
Grignani, Palmerini, Dileo, Asaftei, D'Ambrosio, Pignochino, Mercuri, Picci, Fagioli, Casali (bib11) 2012; 23
Maretty-Nielsen, Aggerholm-Pedersen, Keller, Safwat, Baerentzen, Pedersen (bib17) 2013; 5
Wong, Houghton, Kirsch, Finkelstein, Monjazeb, Xu-Welliver, Dicker, Ahmed, Vikram, Teicher (bib23) 2014; 106
Kubo, Piperdi, Rosenblum, Antonescu, Chen, Kim, Huvos, Sowers, Meyers, Healey (bib8) 2008; 112
Kager, Zoubek, Potschger, Kastner, Flege, Kempf-Bielack, Branscheid, Kotz, Salzer-Kuntschik, Winkelmann (bib1) 2003; 21
van der Graaf, Blay, Chawla, Kim, Bui-Nguyen, Casali, Schoffski, Aglietta, Staddon, Beppu (bib4) 2012; 379
Duffaud, Mir, Boudou-Rouquette, Piperno-Neumann, Penel, Bompas, Delcambre, Kalbacher, Italiano, Collard (bib20) 2019; 20
Longhi, Paioli, Palmerini, Cesari, Abate, Setola, Spinnato, Donati, Hompland, Boye (bib16) 2019; 58
(bib2) 2014; 25
Alcindor (bib14) 2015; 54
Manara, Nicoletti, Zambelli, Ventura, Guerzoni, Landuzzi, Lollini, Maira, Garcia-Echeverria, Mercuri, Picci (bib9) 2010; 16
McGary, Weber, Mills, Doucet, Lewis, Lev, Fidler, Bar-Eli (bib7) 2002; 8
McGary (10.1016/j.tranon.2019.12.001_bib7) 2002; 8
Manara (10.1016/j.tranon.2019.12.001_bib9) 2010; 16
Kubo (10.1016/j.tranon.2019.12.001_bib8) 2008; 112
Alcindor (10.1016/j.tranon.2019.12.001_bib14) 2015; 54
Duffaud (10.1016/j.tranon.2019.12.001_bib20) 2019; 20
Urbonas (10.1016/j.tranon.2019.12.001_bib21) 2019; 30
Schutz (10.1016/j.tranon.2019.12.001_bib3) 2011; 77
Raciborska (10.1016/j.tranon.2019.12.001_bib12) 2018; 35
Grignani (10.1016/j.tranon.2019.12.001_bib13) 2015; 16
Safwat (10.1016/j.tranon.2019.12.001_bib15) 2014; 53
Fox (10.1016/j.tranon.2019.12.001_bib18) 2010; 28
Wong (10.1016/j.tranon.2019.12.001_bib23) 2014; 106
Seto (10.1016/j.tranon.2019.12.001_bib19) 2019; 7
Grignani (10.1016/j.tranon.2019.12.001_bib11) 2012; 23
Yukata (10.1016/j.tranon.2019.12.001_bib10) 2005; 25
Goyal (10.1016/j.tranon.2019.12.001_bib22) 2012; 2012
Coens (10.1016/j.tranon.2019.12.001_bib5) 2015; 121
Abdeen (10.1016/j.tranon.2019.12.001_bib6) 2009; 115
Kager (10.1016/j.tranon.2019.12.001_bib1) 2003; 21
van der Graaf (10.1016/j.tranon.2019.12.001_bib4) 2012; 379
Longhi (10.1016/j.tranon.2019.12.001_bib16) 2019; 58
(10.1016/j.tranon.2019.12.001_bib2) 2014; 25
Maretty-Nielsen (10.1016/j.tranon.2019.12.001_bib17) 2013; 5
References_xml – volume: 5
  start-page: 45
  year: 2013
  end-page: 56
  ident: bib17
  article-title: Population-based Aarhus Sarcoma Registry: validity, completeness of registration, and incidence of bone and soft tissue sarcomas in western Denmark
  publication-title: Clin Epidemiol
  contributor:
    fullname: Pedersen
– volume: 21
  start-page: 2011
  year: 2003
  end-page: 2018
  ident: bib1
  article-title: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols
  publication-title: J Clin Oncol
  contributor:
    fullname: Winkelmann
– volume: 25
  start-page: 955
  year: 2005
  end-page: 957
  ident: bib10
  article-title: Differential expression of VEGF isoforms and VEGF receptors in cartilaginous tumors
  publication-title: Anticancer Res
  contributor:
    fullname: Yasui
– volume: 23
  start-page: 508
  year: 2012
  end-page: 516
  ident: bib11
  article-title: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
  publication-title: Lancet Oncol
  contributor:
    fullname: Casali
– volume: 7
  year: 2019
  ident: bib19
  article-title: Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California
  publication-title: Med Sci (Basel)
  contributor:
    fullname: Pan
– volume: 25
  year: 2014
  ident: bib2
  article-title: Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
  publication-title: Ann Oncol
– volume: 115
  start-page: 5243
  year: 2009
  end-page: 5250
  ident: bib6
  article-title: Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma
  publication-title: Cancer
  contributor:
    fullname: Gorlick
– volume: 112
  start-page: 2119
  year: 2008
  end-page: 2129
  ident: bib8
  article-title: Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma
  publication-title: Cancer
  contributor:
    fullname: Healey
– volume: 58
  start-page: 124
  year: 2019
  end-page: 128
  ident: bib16
  article-title: Pazopanib in relapsed osteosarcoma patients: report on 15 cases
  publication-title: Acta Oncol
  contributor:
    fullname: Boye
– volume: 77
  start-page: 163
  year: 2011
  end-page: 171
  ident: bib3
  article-title: Pazopanib: clinical development of a potent anti-angiogenic drug
  publication-title: Crit Rev Oncol Hematol
  contributor:
    fullname: Sternberg
– volume: 20
  start-page: 120
  year: 2019
  end-page: 133
  ident: bib20
  article-title: Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
  publication-title: Lancet Oncol
  contributor:
    fullname: Collard
– volume: 16
  start-page: 530
  year: 2010
  end-page: 540
  ident: bib9
  article-title: NVP-BEZ235 as a new therapeutic option for sarcomas
  publication-title: Clin Cancer Res
  contributor:
    fullname: Picci
– volume: 106
  year: 2014
  ident: bib23
  article-title: Combining targeted agents with modern radiotherapy in soft tissue sarcomas
  publication-title: J Natl Cancer Inst
  contributor:
    fullname: Teicher
– volume: 35
  start-page: 126
  year: 2018
  ident: bib12
  article-title: Sorafenib in patients with progressed and refractory bone tumors
  publication-title: Med Oncol (Northwood, London, England)
  contributor:
    fullname: Bilska
– volume: 2012
  start-page: 896202
  year: 2012
  ident: bib22
  article-title: Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with pazopanib
  publication-title: ISRN Oncol
  contributor:
    fullname: Haffty
– volume: 379
  start-page: 1879
  year: 2012
  end-page: 1886
  ident: bib4
  article-title: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
  publication-title: Lancet (London, England)
  contributor:
    fullname: Beppu
– volume: 28
  start-page: 5174
  year: 2010
  end-page: 5181
  ident: bib18
  article-title: A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
  publication-title: J Clin Oncol
  contributor:
    fullname: Marotti
– volume: 53
  start-page: 1451
  year: 2014
  end-page: 1454
  ident: bib15
  article-title: Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients
  publication-title: Acta Oncol (Stockholm, Sweden)
  contributor:
    fullname: Rossen
– volume: 8
  start-page: 3584
  year: 2002
  end-page: 3591
  ident: bib7
  article-title: Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571
  publication-title: Clin Cancer Res
  contributor:
    fullname: Bar-Eli
– volume: 121
  start-page: 2933
  year: 2015
  end-page: 2941
  ident: bib5
  article-title: Health-related quality-of-life results from PALETTE: a randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)
  publication-title: Cancer
  contributor:
    fullname: Prins
– volume: 30
  start-page: 317
  year: 2019
  end-page: 324
  ident: bib21
  article-title: Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
  publication-title: Ann Oncol
  contributor:
    fullname: Scudder
– volume: 16
  start-page: 98
  year: 2015
  end-page: 107
  ident: bib13
  article-title: Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
  publication-title: Lancet Oncol
  contributor:
    fullname: Marchesi
– volume: 54
  start-page: 1063
  year: 2015
  end-page: 1064
  ident: bib14
  article-title: Response of refractory Ewing sarcoma to pazopanib
  publication-title: Acta Oncol (Stockholm, Sweden)
  contributor:
    fullname: Alcindor
– volume: 30
  start-page: 317
  issue: 2
  year: 2019
  ident: 10.1016/j.tranon.2019.12.001_bib21
  article-title: Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdy500
  contributor:
    fullname: Urbonas
– volume: 7
  issue: 3
  year: 2019
  ident: 10.1016/j.tranon.2019.12.001_bib19
  article-title: Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California
  publication-title: Med Sci (Basel)
  contributor:
    fullname: Seto
– volume: 2012
  start-page: 896202
  year: 2012
  ident: 10.1016/j.tranon.2019.12.001_bib22
  article-title: Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with pazopanib
  publication-title: ISRN Oncol
  contributor:
    fullname: Goyal
– volume: 8
  start-page: 3584
  issue: 11
  year: 2002
  ident: 10.1016/j.tranon.2019.12.001_bib7
  article-title: Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571
  publication-title: Clin Cancer Res
  contributor:
    fullname: McGary
– volume: 16
  start-page: 530
  issue: 2
  year: 2010
  ident: 10.1016/j.tranon.2019.12.001_bib9
  article-title: NVP-BEZ235 as a new therapeutic option for sarcomas
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-0816
  contributor:
    fullname: Manara
– volume: 23
  start-page: 508
  issue: 2
  year: 2012
  ident: 10.1016/j.tranon.2019.12.001_bib11
  article-title: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
  publication-title: Lancet Oncol
  contributor:
    fullname: Grignani
– volume: 16
  start-page: 98
  issue: 1
  year: 2015
  ident: 10.1016/j.tranon.2019.12.001_bib13
  article-title: Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)71136-2
  contributor:
    fullname: Grignani
– volume: 58
  start-page: 124
  issue: 1
  year: 2019
  ident: 10.1016/j.tranon.2019.12.001_bib16
  article-title: Pazopanib in relapsed osteosarcoma patients: report on 15 cases
  publication-title: Acta Oncol
  doi: 10.1080/0284186X.2018.1503714
  contributor:
    fullname: Longhi
– volume: 112
  start-page: 2119
  issue: 10
  year: 2008
  ident: 10.1016/j.tranon.2019.12.001_bib8
  article-title: Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma
  publication-title: Cancer
  doi: 10.1002/cncr.23437
  contributor:
    fullname: Kubo
– volume: 25
  start-page: 955
  issue: 2A
  year: 2005
  ident: 10.1016/j.tranon.2019.12.001_bib10
  article-title: Differential expression of VEGF isoforms and VEGF receptors in cartilaginous tumors
  publication-title: Anticancer Res
  contributor:
    fullname: Yukata
– volume: 106
  issue: 11
  year: 2014
  ident: 10.1016/j.tranon.2019.12.001_bib23
  article-title: Combining targeted agents with modern radiotherapy in soft tissue sarcomas
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/dju329
  contributor:
    fullname: Wong
– volume: 115
  start-page: 5243
  issue: 22
  year: 2009
  ident: 10.1016/j.tranon.2019.12.001_bib6
  article-title: Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma
  publication-title: Cancer
  doi: 10.1002/cncr.24562
  contributor:
    fullname: Abdeen
– volume: 77
  start-page: 163
  issue: 3
  year: 2011
  ident: 10.1016/j.tranon.2019.12.001_bib3
  article-title: Pazopanib: clinical development of a potent anti-angiogenic drug
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2010.02.012
  contributor:
    fullname: Schutz
– volume: 25
  issue: Suppl 3
  year: 2014
  ident: 10.1016/j.tranon.2019.12.001_bib2
  article-title: Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
  publication-title: Ann Oncol
– volume: 379
  start-page: 1879
  issue: 9829
  year: 2012
  ident: 10.1016/j.tranon.2019.12.001_bib4
  article-title: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
  publication-title: Lancet (London, England)
  doi: 10.1016/S0140-6736(12)60651-5
  contributor:
    fullname: van der Graaf
– volume: 28
  start-page: 5174
  issue: 35
  year: 2010
  ident: 10.1016/j.tranon.2019.12.001_bib18
  article-title: A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.30.9674
  contributor:
    fullname: Fox
– volume: 53
  start-page: 1451
  issue: 10
  year: 2014
  ident: 10.1016/j.tranon.2019.12.001_bib15
  article-title: Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients
  publication-title: Acta Oncol (Stockholm, Sweden)
  doi: 10.3109/0284186X.2014.948062
  contributor:
    fullname: Safwat
– volume: 35
  start-page: 126
  issue: 10
  year: 2018
  ident: 10.1016/j.tranon.2019.12.001_bib12
  article-title: Sorafenib in patients with progressed and refractory bone tumors
  publication-title: Med Oncol (Northwood, London, England)
  doi: 10.1007/s12032-018-1180-x
  contributor:
    fullname: Raciborska
– volume: 20
  start-page: 120
  issue: 1
  year: 2019
  ident: 10.1016/j.tranon.2019.12.001_bib20
  article-title: Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(18)30742-3
  contributor:
    fullname: Duffaud
– volume: 21
  start-page: 2011
  issue: 10
  year: 2003
  ident: 10.1016/j.tranon.2019.12.001_bib1
  article-title: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2003.08.132
  contributor:
    fullname: Kager
– volume: 54
  start-page: 1063
  issue: 7
  year: 2015
  ident: 10.1016/j.tranon.2019.12.001_bib14
  article-title: Response of refractory Ewing sarcoma to pazopanib
  publication-title: Acta Oncol (Stockholm, Sweden)
  doi: 10.3109/0284186X.2014.971938
  contributor:
    fullname: Alcindor
– volume: 121
  start-page: 2933
  issue: 17
  year: 2015
  ident: 10.1016/j.tranon.2019.12.001_bib5
  publication-title: Cancer
  doi: 10.1002/cncr.29426
  contributor:
    fullname: Coens
– volume: 5
  start-page: 45
  year: 2013
  ident: 10.1016/j.tranon.2019.12.001_bib17
  article-title: Population-based Aarhus Sarcoma Registry: validity, completeness of registration, and incidence of bone and soft tissue sarcomas in western Denmark
  publication-title: Clin Epidemiol
  doi: 10.2147/CLEP.S41835
  contributor:
    fullname: Maretty-Nielsen
SSID ssj0061922
Score 2.38002
Snippet BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are...
The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed....
BACKGROUNDThe effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are...
BACKGROUND: The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 295
SubjectTerms Original article
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQbyIb9cXEbwW0zTJNp58oCzCiuAK3kKSJrgiXdH14q93pmnV1YMXr21pOjNJZr7myxdCDjVSnyrvs4opm4nIbGYlD5kLklWBl2XucYPz8FoN7sTVvbz_dtQXcsKSPHBy3FGsguBWB85LJ2SlUd8OQFX0XjlbuKRemssOTKU5GFEBT-vJCqFW0W2aa5hdU8gCE9Q-zXXzK7A9EKZLSo12_0xu-l17_qRQfstJl8tkqS0m6WkyYoXMhXqVLAzb5fI1cnJj3wEU12NHxzWFUo-OOl45nUR6NqkDvYWejhyhY9pKhD7RL_njdTK6vBidD7L2yITMS66nWeW5BbsCC6JkOnoZldAMirCoJTgOsB_jtshlLJgDrGSl985VAkY589apYoPMg2vCFqE5d0r50oeiDKJyqsTCycmYR-EkzAM9knUuM89JGMN0jLFHk1xs0MUm50ic65Ez9Ovnsyhr3VyAYJs22OavYPdIv4uKaSuElPnhVeM_mj_ogmhgAOGqiK3D5O3VQO9gfUShukc2U1A_PxImvL6EghbanQn3jBWzd-rxQyPSrXSB6nnb_2H2DlnkCPMbsvgumZ--vIU9qIWmbr_p9h_8sgYh
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ScienceDirect Open Access Journals (Elsevier)
  dbid: IXB
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BTtwwELUQB8Slaim0SwG5EtdoHcf2xj3BoiJUiaoSi7Q3y3bsNlWVILpc-vWdSWxo2gNSr0mUODOTmXnx8zMhpxqpT433RcOULURktrCSh8IFyZrA67r0uMD5-rO6uhWf1nK9RS7yWhikVabcP-b0IVunI_Nkzfld285voPVQAKMghgCSQ6RCHkZtT1zEt17mbIz4gI8zywpBV5WXzw0crw3Ugx5VUEs9_BRMW8Pk8jSo-E-q1L9d6N9kyj-q0-VL8iK1lfR8HPkrshW6PbJznSbOX5OzL_YXwOOudbTtKDR9dJUZ5rSPdNl3gd5AzCNb6ANNYqE_6JMQ8j5ZXX5cXVwVafOEwkuuN0XjuYX3CiyImunoZVRCM2jHopZcQVFXjNuqlLFiDlCTld471wj43pm3TlUHZBtME94SWnKnlK99qOogGqdqbKGcjGUUTkJGmJEim8zcjRIZJnPHvpvRxAZNbEqOFLoZWaJdH69FgevhQH__1SQPm9gEwa0OnNdOyEajrCFg6ei9crZyckYW2StmEi9wq_aZx7_PTjTwKeH8iO1C__DTQHSwBeJRPSNvRqc-DhJS30JCawvPnbh78hbTM137bZDrVrpCHb3D_x7xO7LLEeUPXPEjsr25fwjH0Apt3MkQ678BR5IG4g
  priority: 102
  providerName: Elsevier
Title Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience
URI https://dx.doi.org/10.1016/j.tranon.2019.12.001
https://www.ncbi.nlm.nih.gov/pubmed/31875575
https://search.proquest.com/docview/2330792499
https://pubmed.ncbi.nlm.nih.gov/PMC6931211
https://doaj.org/article/fde42a9e228b45d99262837fcc6ba3b5
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELaAA-qlKvS1LSBX6jWs49fGPZVFIEBahNSttDfLduw2CBJEl0t_fcdODCw9IHHJIS_bM2PPjP35M0JfVYQ-1c4VNZGm4IGYwgjqC-sFqT2tqtLFDc6zc3nyk58txGINibwXJoH2nW3226vr_bb5nbCVN9dunHFi44vZoVQsMpON19H6hLGcovfDb0wIaN4jl4BcSxj0u0h1Wqo080fi6TBgyhMhIrrwkTtKrP0rXun_qPMpePKRNzp-g14PYSQ-6Ku7hdZ8u402Z8NC-Vv0_cL8hXS4bSxuWgxBHp5nRDnuAp52rcc_wMYjOugbHshBr_AD8fE7ND8-mh-eFMNhCYUTVC2L2lEDTfTE84qo4ESQXBEIv4ISVIITl4QaVorAiIUsyQjnrK059G_ijJXsPdoAKfmPCJfUSukq51nleW1lFUMmK0IZuBUwAoxQkUWmb3pKDJ2xYpe6l7aO0tYljZC5EZpGud6_Gwmt043u9pce1KpD7Tk1ylNaWS5qFWkMIXcOzklrmBUjNMla0UNs0Pt8-FXzTPFfshI1dJ24HmJa39390ZTBABfzTzVCH3ql3lcy2weUu6LulVasPgFrTfTcg3V-evGXn9ErGrP6hA3fQRvL2zu_C6HP0u6lKQO4ni6me8ns_wF_DgYg
link.rule.ids 230,315,733,786,790,870,891,2115,3525,27955,27956,45907,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEX3o_laSSu2XUc2405QSuqBbpVJRbUm2U7NgTapCrZS3894yQu3XJAcI3zsmc8_sb-_BnglYrUp8q5rKLSZDxQkxnBfGa9oJVnZZm7uMF5sS_nn_mHQ3G4ASLthelJ-87W0-boeNrU33pu5cmxmyWe2OxgsSNVEZXJZlfgKvZXJlKSPgTgmBKwtEuup3J1GPbbKHaaq37uj8bzYdCZt4SI_MILA1Kv2782Lv2JOy_TJy-MR7u34EuqyUBD-TFddXbqzi6JPP5zVW_DzRGhkrdD8R3Y8M1duLYY1-DvwZsDc4aZdlNbUjcE8SNZJrI6aQPZbhtPPmH3icSj12TUHT0ivzWV78Ny991yZ56N5zBkTjDVZZVjBtvOU89LqoITQXJFEdkFJZhEfCApM0UuQkEtJmBGOGdtxTF0UGesLB7AJja_fwQkZ1ZKVzpflJ5XVpYRjVkR8sCtwOAygSzZQp8Mahs60dC-68GMOppR5yyy8SawHQ12fm_Uyu4vtKdf9diMOlSeM6M8Y6XlolJRIRHT8uCctKawYgJbydx6hB0DnMBX1X_5_MvkHRp7ZVxqMY1vVz81KzB2xtRWTeDh4C3nP5kcD7-75kdrtVgvQe_olb9Hb3j830--gOvz5WJP773f__gEbrA4edBT0J_CZne68s8QYXX2ed-ffgFzSyYU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLagSBUXdsqwGolrZhzH9sScoIVRWaYaiUGquFheIdAmo5K59NfznMRlphyQes3m2O_5-Xv2588IvZKR-uSszRwROmOB6Exz6jPjOXGelmVu4wbn-ZE4_Mo-HvPjjaO-OtK-NdW4Pjkd19WPjlu5OrWTxBObLOYHQhZRmWyycmFyHd2APkunKVHvg3BMC2jaKdfRuVoI_U0UPM1lN_9H4hkx4NBTziPHcGNQ6rT7t8amf7HnZQrlxpg0u42-pdr0VJRf43Vrxvb8ktDjlap7B90akCp-2z9yF13z9T20Ox_W4u-jNwt9Dhl3XRlc1RhwJF4m0jpuAt5vao-_QDeKBKTXeNAfPcF_tZUfoOXs_fLgMBvOY8gsp7LNnKUa2s8Tz0oig-VBMEkA4QXJqQCcIAjVRc5DQQwkYppba4xjEEKI1UYUD9EOmMA_QjinRghbWl-UnjkjyojKDA95YIZDkBmhLNlDrXrVDZXoaD9Vb0oVTalyGll5I7QfjXbxbNTM7i40Z9_V0JQqOM-olp7S0jDuZFRKhPQ8WCuMLgwfoWkyuRrgRw8r4FPVf4p_mTxEQe-MSy669s36t6IFxNCY4soR2us95uInk_NBuVu-tFWL7TvgIZ0C-OARj6_85gu0u3g3U58_HH16gm7SOIfQMdGfop32bO2fAdBqzfOuS_0BpWkolA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pazopanib+in+the+Treatment+of+Bone+Sarcomas%3A+Clinical+Experience&rft.jtitle=Translational+oncology&rft.au=Aggerholm-Pedersen%2C+Ninna&rft.au=Rossen%2C+Phillip&rft.au=Rose%2C+Hanne&rft.au=Safwat%2C+Akmal&rft.date=2020-02-01&rft.issn=1936-5233&rft.volume=13&rft.issue=2&rft.spage=295&rft_id=info:doi/10.1016%2Fj.tranon.2019.12.001&rft_id=info%3Apmid%2F31875575&rft.externalDocID=31875575
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1936-5233&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1936-5233&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1936-5233&client=summon